Aug 26,2021

Data MATRIX Introduces an AI-Operated Patient Survival Assessment Tool

Data MATRIX, a sole Real-World Evidence solutions provider in Russia, has presented a predictive analytics tool for estimating patient survival based on Real-World Data. An important feature of the presented tool for predictive analysis of Real-World Data is its countrywide potential, and the ability to collect and analyze data on different patient cohorts. The company's medical director, Polina Shpigotskaya, held a live demonstration of the tool's capabilities to the participants, using breast cancer patients as an example. However, the product is also suitable for other therapeutic areas.

PRODUCT

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 31,2021

Veterans Prostate Cancer Awareness Partnership – Massive Bio

Massive Bio today announced it has entered a partnership with Veterans Prostate Cancer Awareness (VPCa), and Self-Care Catalysts to increase clinical trial and real-world evidence research participation in prostate cancer. This will help put Massive Bio in a position to attract new patients and will provide Veterans Prostate Cancer Awareness and Self-Care Catalysts with new ways to help their members fight cancer.

COLLABORATION PARTNERSHIP

#institution

#rwe

View Analyst & Ambassador Comments
Go to original news
Oct 21,2021

Roche is Validating the Utility of Real-World Evidence as a comparator to Single-arm Clinical Trials

Over the past decade or so, real-world evidence (RWE) has emerged as an extremely important tool for bringing innovative treatments to patients. New research from Roche, one of the largest and most influential life science companies in the world, is making a very strong argument in RWE’s favor. In a relatively rare subpopulation of patients carrying the ALK driver mutation in advanced non-small cell lung cancer (NSCLC), Roche performed a single arm trial for the targeted therapy alectinib. In oncology, it is relatively hard to recruit patients with driver mutation positive disease into trials, so the purpose of Roche’s trial was to try to provide this medicine faster to patients who urgently need it.

CLINICAL STUDY

#rwe

View Analyst & Ambassador Comments
Go to original news
Jul 01,2020

NICE Partners with Flatiron Health to Develop Real-World Evidence Research Methodologies

The National Institute for Health and Care Excellence (NICE) is partnering with Flatiron Health, an oncology research and technology company, to explore how real-world evidence (RWE) can inform the clinical and cost effectiveness of health technologies. Flatiron Health and NICE experts will together conduct research that leverages Flatiron expertise and evidence generated from Flatiron’s electronic-health-record (EHR)-derived database; no individual patient data will be shared. An initial research project already underway will compare survival estimates from clinical trials to survival data observed in actual patient records to evaluate opportunities to reduce uncertainty in the estimation of long-term outcomes.

COLLABORATION PARTNERSHIP

#r&d

#rwe

#rwd

View Analyst & Ambassador Comments
Go to original news
Feb 01,2019

The FDA and Flatiron Health Expand Real-World Data Cancer Research Collaboration

Flatiron Health and the Information Exchange and Data Transformation (INFORMED) Program at the U.S. Food and Drug Administration (FDA) today announced a two-year renewal and expansion of their research collaboration agreement. The collaboration, which began in 2016, has enabled the FDA to better understand how real-world evidence (RWE), derived from de-identified patient datasets curated from electronic health records, can support regulatory decision-making.

COLLABORATION PARTNERSHIP

#r&d

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Apr 01,2019

Foundation Medicine and Flatiron Health Publish Validation of Clinico-Genomic Database as a Platform to Advance Oncology Therapeutics Development and Personalized Cancer Care

Foundation Medicine and Flatiron Health today announced the publication of study results in the Journal of the American Medical Association validating that real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights. These insights can serve as real-world evidence to advance research and discovery in oncology, and may also ultimately inform clinical guidelines.

CLINICAL STUDY

#platform

#rwe

View Analyst & Ambassador Comments
Go to original news
Aug 01,2019

Flatiron Health Announces Three Publications Studying a Feasible, Reliable, Scalable and Meaningful Real-World Progression Endpoint for Oncology Research

Today, Flatiron Health announced a series of three research publications that developed and evaluated a new approach to capture when a patient’s cancer has worsened based on information contained in the electronic health record (EHR). These manuscripts illustrate the potential impact for research conducted from data collected as part of routine clinical care (real-world data).

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
May 01,2018

Pivotal Study Validates Real-World Mortality Endpoint for Oncology Research

Today, Flatiron Health, a market leader in the curation of regulatory-grade real-world data for cancer research and real-world evidence (RWE) generation, announced the publication of a pivotal study validating the quality of Flatiron’s mortality endpoint and illustrating the potential impact for research conducted with contemporary real-world datasets. The published study details how investigators created a novel real-world mortality endpoint using multiple data sources to supplement Flatiron’s curated electronic health record data, collected from the company’s network of over 2,500 oncology clinicians.

CLINICAL STUDY

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
May 01,2018

Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement

Bristol-Myers Squibb and Flatiron Health expanded their relationship today by announcing a three-year collaboration agreement. Bristol-Myers Squibb will use Flatiron’s real-world data to accelerate its research and development efforts, as well as improve its ability to generate additional evidence on the use of its cancer medicines outside of clinical trials. With the expanded collaboration, the two companies intend to form a joint Scientific Advisory Board to advance the use of RWE for regulatory decision making.

COLLABORATION PARTNERSHIP

#product & service

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Feb 01,2018

Roche to Acquire Flatiron Health to Accelerate Industry-Wide Development and Delivery of Breakthrough Medicines for Patients with Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Flatiron Health, Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018. Under the terms of the agreement, Roche will make a payment of USD 1.9 billion to Flatiron Health on a fully diluted basis, subject to certain adjustments.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWE